MCK to ABC: 5 healthcare stocks that returned strong 1-year, YTD gains

Highlights: Pfizer Inc. (NYSE: PFE) reported a strong Q1, FY 2022, revenue of US$25.7 billion on Tuesday. Pfizer posted 82% operational revenue growth in the first quarter of 2022. Pfizer’s direct sales of the Comirnaty vaccine grew to ...

Highlights Texas-based Vaxxinity is a biotechnology company specializing in vaccines for chronic disorders and infectious diseases. The company launched its IPO in November 2021. The stock price has declined by over 72% since the IPO.  ...

Highlights: Eli Lilly and Company (LLY) reported a 15% revenue growth in the first quarter. Eli Lilly’s Covid-19 vaccine revenue grew to US$660 million. Its key growth products are Tirzepatide, Trulicity, Verzenio, Jardiance, and Taltz. ...

Highlights  Evoke Pharma is a specialty pharmaceutical company focused on drugs for treating gastrointestinal disorders and diseases.   The US Food and Drug Administration (FDA) has granted new drug product exclusivity for the company...

Highlights The company posted core operating income of US$4.08 billion. The revenue for its generic drug unit Sandoz was US$538 million. Novartis announced a share buyback program in December 2021. Swiss drugmaker Novartis AG (NYSE: NVS) ...

Highlights  Veru Inc. (VERU) is a biopharmaceutical company focused on urology and oncology. VERU stock rose 80.51% YTD and 18.88% in one year. The stock has a market capitalization of US$1.03 billion. Shares of biopharmaceuticals co...

Highlights  Sierra Oncology, Inc. (NASDAQ: SRRA) stock grew 150.14% year-to- Voyager Therapeutics, Inc. (NASDAQ: VYGR) generated a 17% return YTD. Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) stock rose 257.04% YTD.  Biotechn...

French biopharmaceutical company Erytech Pharma SA (NASDAQ: ERYP) stock jumped over 57% in premarket on Monday after it announced selling its US facility to Catalent Inc. (CTLT). Lyon-based Erytech said that it sold its US cell therapy unit to Cat...

Highlights  AlloVir, Inc. (NASDAQ: ALVR) is a late clinical-stage cell therapy company. On Wednesday, it announced receiving Regenerative Medicine Advanced Therapy (RMAT) designation from FDA for posoleucel therapy. FDA also granted the O...

Highlights: Veeva Systems Inc. (NYSE: VEEV) revenue increased by 22% YoY in Q4, FY22. DexCom, Inc. (NASDAQ: DXCM) will release its first-quarter fiscal 2022 financial results on April 28. Illumina, Inc. (NASDAQ: ILMN) will release its first-qu...